Kyverna Therapeutics’ (KYTX) Neutral Rating Reiterated at HC Wainwright

Kyverna Therapeutics (NASDAQ:KYTX)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $7.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 6.06% from the stock’s current price.

Separately, JPMorgan Chase & Co. cut their target price on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Kyverna Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $34.40.

Kyverna Therapeutics Stock Down 0.9 %

KYTX stock opened at $6.60 on Thursday. Kyverna Therapeutics has a 12 month low of $6.30 and a 12 month high of $35.06. The firm’s fifty day simple moving average is $8.02 and its 200-day simple moving average is $13.92.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.03. On average, equities analysts anticipate that Kyverna Therapeutics will post -3.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Kyverna Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Bain Capital Life Sciences Investors LLC purchased a new stake in shares of Kyverna Therapeutics during the first quarter worth about $78,590,000. Jennison Associates LLC purchased a new stake in Kyverna Therapeutics during the 1st quarter worth approximately $34,743,000. Novo Holdings A S raised its holdings in shares of Kyverna Therapeutics by 150.0% during the second quarter. Novo Holdings A S now owns 1,750,000 shares of the company’s stock valued at $13,125,000 after acquiring an additional 1,050,000 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Kyverna Therapeutics in the first quarter valued at approximately $23,093,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Kyverna Therapeutics in the first quarter worth approximately $15,041,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.